The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis
Summary Background Faecal microbiota transplantation is an experimental approach for the treatment of patients with ulcerative colitis. Although there is growing evidence that faecal microbiota transplantation is effective in this disease, factors affecting its response are unknown. Aims To establis...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2018-01, Vol.47 (1), p.67-77 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 77 |
|---|---|
| container_issue | 1 |
| container_start_page | 67 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 47 |
| creator | Kump, P. Wurm, P. Gröchenig, H. P. Wenzl, H. Petritsch, W. Halwachs, B. Wagner, M. Stadlbauer, V. Eherer, A. Hoffmann, K. M. Deutschmann, A. Reicht, G. Reiter, L. Slawitsch, P. Gorkiewicz, G. Högenauer, C. |
| description | Summary
Background
Faecal microbiota transplantation is an experimental approach for the treatment of patients with ulcerative colitis. Although there is growing evidence that faecal microbiota transplantation is effective in this disease, factors affecting its response are unknown.
Aims
To establish a faecal microbiota transplantation treatment protocol in ulcerative colitis patients, and to investigate which patient or donor factors are responsible for the treatment success.
Methods
This is an open controlled trial of repeated faecal microbiota transplantation after antibiotic pre‐treatment (FMT‐group, n = 17) vs antibiotic pre‐treatment only (AB‐group, n = 10) in 27 therapy refractory ulcerative colitis patients over 90 days. Faecal samples of donors and patients were analysed by 16SrRNA gene‐based microbiota analysis.
Results
In the FMT‐group, 10/17 (59%) of patients showed a response and 4/17 (24%) a remission to faecal microbiota transplantation. Response to faecal microbiota transplantation was mainly influenced by the taxonomic composition of the donor's microbiota. Stool of donors with a high bacterial richness (observed species remission 946 ± 93 vs no response 797 ± 181 at 15367 rps) and a high relative abundance of Akkermansia muciniphila (3.3 ± 3.1% vs 0.1 ± 0.2%), unclassified Ruminococcaceae (13.8 ± 5.0% vs 7.5 ± 3.7%), and Ruminococcus spp. (4.9 ± 3.5% vs 1.0 ± 0.7%) were more likely to induce remission. In contrast antibiotic treatment alone (AB‐group) was poorly tolerated, probably because of a sustained decrease of intestinal microbial richness.
Conclusions
The taxonomic composition of the donor's intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in ulcerative colitis patients. The design of specific microbial preparation might lead to new treatments for ulcerative colitis. |
| doi_str_mv | 10.1111/apt.14387 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5765501</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1974926095</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4437-a725dd9bfad66278cd00fc32062cd1dca82229dbd6a17db61b443fc25ae910763</originalsourceid><addsrcrecordid>eNp1ks1u1DAUhSMEokNhwQsgS2xgkdZ2EmeyQaoq_qRKsBjW1o1_Wo8SO9hOIQ_G-3EnUyqKRBaO5Pvd4-PjWxQvGT1j-J3DlM9YXW3bR8WGVaIpOa3E42JDuehKvmXVSfEspT2lVLSUPy1OeEcbzqt2U_za3RiS4WfwYXSKqDBOIbnsgifBkoxFjaVInM8mZedhIMjF0LuQgbhEgIywR8CCyitnh9l45fz12m2sdQrUclCzYNTD_hzBp2kAn2E90vlDU4RpIdHYuEouZB4U7mV3a9DfgObS8-KJhSGZF3f_0-Lbh_e7y0_l1ZePny8vrkpV11VbQssbrbveghaCt1ulKbWq4lRwpZlWsOWcd7rXAlire8F6bLOKN2A6RltRnRbvjrrT3I9GK-PR8SCn6EaIiwzg5MOKdzfyOtzKphVNQxkKvLkTiOH7jAnK0SVlBryyCXOSrGtqKmpcEH39D7oPc8TAD1Rbd1zQrkHq7ZHCDFPCkO7NMCoPwyBxGOQ6DMi--tv9Pfnn9RE4PwI_3GCW_yvJi6-7o-Rvq2bE4A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1974926095</pqid></control><display><type>article</type><title>The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Kump, P. ; Wurm, P. ; Gröchenig, H. P. ; Wenzl, H. ; Petritsch, W. ; Halwachs, B. ; Wagner, M. ; Stadlbauer, V. ; Eherer, A. ; Hoffmann, K. M. ; Deutschmann, A. ; Reicht, G. ; Reiter, L. ; Slawitsch, P. ; Gorkiewicz, G. ; Högenauer, C.</creator><creatorcontrib>Kump, P. ; Wurm, P. ; Gröchenig, H. P. ; Wenzl, H. ; Petritsch, W. ; Halwachs, B. ; Wagner, M. ; Stadlbauer, V. ; Eherer, A. ; Hoffmann, K. M. ; Deutschmann, A. ; Reicht, G. ; Reiter, L. ; Slawitsch, P. ; Gorkiewicz, G. ; Högenauer, C.</creatorcontrib><description>Summary
Background
Faecal microbiota transplantation is an experimental approach for the treatment of patients with ulcerative colitis. Although there is growing evidence that faecal microbiota transplantation is effective in this disease, factors affecting its response are unknown.
Aims
To establish a faecal microbiota transplantation treatment protocol in ulcerative colitis patients, and to investigate which patient or donor factors are responsible for the treatment success.
Methods
This is an open controlled trial of repeated faecal microbiota transplantation after antibiotic pre‐treatment (FMT‐group, n = 17) vs antibiotic pre‐treatment only (AB‐group, n = 10) in 27 therapy refractory ulcerative colitis patients over 90 days. Faecal samples of donors and patients were analysed by 16SrRNA gene‐based microbiota analysis.
Results
In the FMT‐group, 10/17 (59%) of patients showed a response and 4/17 (24%) a remission to faecal microbiota transplantation. Response to faecal microbiota transplantation was mainly influenced by the taxonomic composition of the donor's microbiota. Stool of donors with a high bacterial richness (observed species remission 946 ± 93 vs no response 797 ± 181 at 15367 rps) and a high relative abundance of Akkermansia muciniphila (3.3 ± 3.1% vs 0.1 ± 0.2%), unclassified Ruminococcaceae (13.8 ± 5.0% vs 7.5 ± 3.7%), and Ruminococcus spp. (4.9 ± 3.5% vs 1.0 ± 0.7%) were more likely to induce remission. In contrast antibiotic treatment alone (AB‐group) was poorly tolerated, probably because of a sustained decrease of intestinal microbial richness.
Conclusions
The taxonomic composition of the donor's intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in ulcerative colitis patients. The design of specific microbial preparation might lead to new treatments for ulcerative colitis.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.14387</identifier><identifier>PMID: 29052237</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adult ; Anti-Bacterial Agents - administration & dosage ; Antibiotics ; Bacteria ; Colitis, Ulcerative - therapy ; Colon ; Donors ; Fecal Microbiota Transplantation - methods ; Feces - microbiology ; Gastrointestinal Microbiome ; Humans ; Inflammatory bowel disease ; Intestinal microflora ; Intestine ; Male ; Microbiota ; Middle Aged ; Original ; Prospective Studies ; Relative abundance ; Remission ; Remission Induction ; Ruminococcus ; Taxonomy ; Transplantation ; Treatment Outcome ; Ulcerative colitis ; Ulcerative Colitis and Faecal Transplant Donor Microbiota ; Young Adult</subject><ispartof>Alimentary pharmacology & therapeutics, 2018-01, Vol.47 (1), p.67-77</ispartof><rights>2017 The Authors. Published by John Wiley & Sons Ltd.</rights><rights>2017 The Authors. Alimentary Pharmacology & Therapeutics Published by John Wiley & Sons Ltd.</rights><rights>Copyright © 2018 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4437-a725dd9bfad66278cd00fc32062cd1dca82229dbd6a17db61b443fc25ae910763</citedby><cites>FETCH-LOGICAL-c4437-a725dd9bfad66278cd00fc32062cd1dca82229dbd6a17db61b443fc25ae910763</cites><orcidid>0000-0003-4566-0806 ; 0000-0003-1149-4782</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fapt.14387$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fapt.14387$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29052237$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kump, P.</creatorcontrib><creatorcontrib>Wurm, P.</creatorcontrib><creatorcontrib>Gröchenig, H. P.</creatorcontrib><creatorcontrib>Wenzl, H.</creatorcontrib><creatorcontrib>Petritsch, W.</creatorcontrib><creatorcontrib>Halwachs, B.</creatorcontrib><creatorcontrib>Wagner, M.</creatorcontrib><creatorcontrib>Stadlbauer, V.</creatorcontrib><creatorcontrib>Eherer, A.</creatorcontrib><creatorcontrib>Hoffmann, K. M.</creatorcontrib><creatorcontrib>Deutschmann, A.</creatorcontrib><creatorcontrib>Reicht, G.</creatorcontrib><creatorcontrib>Reiter, L.</creatorcontrib><creatorcontrib>Slawitsch, P.</creatorcontrib><creatorcontrib>Gorkiewicz, G.</creatorcontrib><creatorcontrib>Högenauer, C.</creatorcontrib><title>The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Background
Faecal microbiota transplantation is an experimental approach for the treatment of patients with ulcerative colitis. Although there is growing evidence that faecal microbiota transplantation is effective in this disease, factors affecting its response are unknown.
Aims
To establish a faecal microbiota transplantation treatment protocol in ulcerative colitis patients, and to investigate which patient or donor factors are responsible for the treatment success.
Methods
This is an open controlled trial of repeated faecal microbiota transplantation after antibiotic pre‐treatment (FMT‐group, n = 17) vs antibiotic pre‐treatment only (AB‐group, n = 10) in 27 therapy refractory ulcerative colitis patients over 90 days. Faecal samples of donors and patients were analysed by 16SrRNA gene‐based microbiota analysis.
Results
In the FMT‐group, 10/17 (59%) of patients showed a response and 4/17 (24%) a remission to faecal microbiota transplantation. Response to faecal microbiota transplantation was mainly influenced by the taxonomic composition of the donor's microbiota. Stool of donors with a high bacterial richness (observed species remission 946 ± 93 vs no response 797 ± 181 at 15367 rps) and a high relative abundance of Akkermansia muciniphila (3.3 ± 3.1% vs 0.1 ± 0.2%), unclassified Ruminococcaceae (13.8 ± 5.0% vs 7.5 ± 3.7%), and Ruminococcus spp. (4.9 ± 3.5% vs 1.0 ± 0.7%) were more likely to induce remission. In contrast antibiotic treatment alone (AB‐group) was poorly tolerated, probably because of a sustained decrease of intestinal microbial richness.
Conclusions
The taxonomic composition of the donor's intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in ulcerative colitis patients. The design of specific microbial preparation might lead to new treatments for ulcerative colitis.</description><subject>Adult</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Antibiotics</subject><subject>Bacteria</subject><subject>Colitis, Ulcerative - therapy</subject><subject>Colon</subject><subject>Donors</subject><subject>Fecal Microbiota Transplantation - methods</subject><subject>Feces - microbiology</subject><subject>Gastrointestinal Microbiome</subject><subject>Humans</subject><subject>Inflammatory bowel disease</subject><subject>Intestinal microflora</subject><subject>Intestine</subject><subject>Male</subject><subject>Microbiota</subject><subject>Middle Aged</subject><subject>Original</subject><subject>Prospective Studies</subject><subject>Relative abundance</subject><subject>Remission</subject><subject>Remission Induction</subject><subject>Ruminococcus</subject><subject>Taxonomy</subject><subject>Transplantation</subject><subject>Treatment Outcome</subject><subject>Ulcerative colitis</subject><subject>Ulcerative Colitis and Faecal Transplant Donor Microbiota</subject><subject>Young Adult</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1ks1u1DAUhSMEokNhwQsgS2xgkdZ2EmeyQaoq_qRKsBjW1o1_Wo8SO9hOIQ_G-3EnUyqKRBaO5Pvd4-PjWxQvGT1j-J3DlM9YXW3bR8WGVaIpOa3E42JDuehKvmXVSfEspT2lVLSUPy1OeEcbzqt2U_za3RiS4WfwYXSKqDBOIbnsgifBkoxFjaVInM8mZedhIMjF0LuQgbhEgIywR8CCyitnh9l45fz12m2sdQrUclCzYNTD_hzBp2kAn2E90vlDU4RpIdHYuEouZB4U7mV3a9DfgObS8-KJhSGZF3f_0-Lbh_e7y0_l1ZePny8vrkpV11VbQssbrbveghaCt1ulKbWq4lRwpZlWsOWcd7rXAlire8F6bLOKN2A6RltRnRbvjrrT3I9GK-PR8SCn6EaIiwzg5MOKdzfyOtzKphVNQxkKvLkTiOH7jAnK0SVlBryyCXOSrGtqKmpcEH39D7oPc8TAD1Rbd1zQrkHq7ZHCDFPCkO7NMCoPwyBxGOQ6DMi--tv9Pfnn9RE4PwI_3GCW_yvJi6-7o-Rvq2bE4A</recordid><startdate>201801</startdate><enddate>201801</enddate><creator>Kump, P.</creator><creator>Wurm, P.</creator><creator>Gröchenig, H. P.</creator><creator>Wenzl, H.</creator><creator>Petritsch, W.</creator><creator>Halwachs, B.</creator><creator>Wagner, M.</creator><creator>Stadlbauer, V.</creator><creator>Eherer, A.</creator><creator>Hoffmann, K. M.</creator><creator>Deutschmann, A.</creator><creator>Reicht, G.</creator><creator>Reiter, L.</creator><creator>Slawitsch, P.</creator><creator>Gorkiewicz, G.</creator><creator>Högenauer, C.</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4566-0806</orcidid><orcidid>https://orcid.org/0000-0003-1149-4782</orcidid></search><sort><creationdate>201801</creationdate><title>The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis</title><author>Kump, P. ; Wurm, P. ; Gröchenig, H. P. ; Wenzl, H. ; Petritsch, W. ; Halwachs, B. ; Wagner, M. ; Stadlbauer, V. ; Eherer, A. ; Hoffmann, K. M. ; Deutschmann, A. ; Reicht, G. ; Reiter, L. ; Slawitsch, P. ; Gorkiewicz, G. ; Högenauer, C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4437-a725dd9bfad66278cd00fc32062cd1dca82229dbd6a17db61b443fc25ae910763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Antibiotics</topic><topic>Bacteria</topic><topic>Colitis, Ulcerative - therapy</topic><topic>Colon</topic><topic>Donors</topic><topic>Fecal Microbiota Transplantation - methods</topic><topic>Feces - microbiology</topic><topic>Gastrointestinal Microbiome</topic><topic>Humans</topic><topic>Inflammatory bowel disease</topic><topic>Intestinal microflora</topic><topic>Intestine</topic><topic>Male</topic><topic>Microbiota</topic><topic>Middle Aged</topic><topic>Original</topic><topic>Prospective Studies</topic><topic>Relative abundance</topic><topic>Remission</topic><topic>Remission Induction</topic><topic>Ruminococcus</topic><topic>Taxonomy</topic><topic>Transplantation</topic><topic>Treatment Outcome</topic><topic>Ulcerative colitis</topic><topic>Ulcerative Colitis and Faecal Transplant Donor Microbiota</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kump, P.</creatorcontrib><creatorcontrib>Wurm, P.</creatorcontrib><creatorcontrib>Gröchenig, H. P.</creatorcontrib><creatorcontrib>Wenzl, H.</creatorcontrib><creatorcontrib>Petritsch, W.</creatorcontrib><creatorcontrib>Halwachs, B.</creatorcontrib><creatorcontrib>Wagner, M.</creatorcontrib><creatorcontrib>Stadlbauer, V.</creatorcontrib><creatorcontrib>Eherer, A.</creatorcontrib><creatorcontrib>Hoffmann, K. M.</creatorcontrib><creatorcontrib>Deutschmann, A.</creatorcontrib><creatorcontrib>Reicht, G.</creatorcontrib><creatorcontrib>Reiter, L.</creatorcontrib><creatorcontrib>Slawitsch, P.</creatorcontrib><creatorcontrib>Gorkiewicz, G.</creatorcontrib><creatorcontrib>Högenauer, C.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kump, P.</au><au>Wurm, P.</au><au>Gröchenig, H. P.</au><au>Wenzl, H.</au><au>Petritsch, W.</au><au>Halwachs, B.</au><au>Wagner, M.</au><au>Stadlbauer, V.</au><au>Eherer, A.</au><au>Hoffmann, K. M.</au><au>Deutschmann, A.</au><au>Reicht, G.</au><au>Reiter, L.</au><au>Slawitsch, P.</au><au>Gorkiewicz, G.</au><au>Högenauer, C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2018-01</date><risdate>2018</risdate><volume>47</volume><issue>1</issue><spage>67</spage><epage>77</epage><pages>67-77</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary
Background
Faecal microbiota transplantation is an experimental approach for the treatment of patients with ulcerative colitis. Although there is growing evidence that faecal microbiota transplantation is effective in this disease, factors affecting its response are unknown.
Aims
To establish a faecal microbiota transplantation treatment protocol in ulcerative colitis patients, and to investigate which patient or donor factors are responsible for the treatment success.
Methods
This is an open controlled trial of repeated faecal microbiota transplantation after antibiotic pre‐treatment (FMT‐group, n = 17) vs antibiotic pre‐treatment only (AB‐group, n = 10) in 27 therapy refractory ulcerative colitis patients over 90 days. Faecal samples of donors and patients were analysed by 16SrRNA gene‐based microbiota analysis.
Results
In the FMT‐group, 10/17 (59%) of patients showed a response and 4/17 (24%) a remission to faecal microbiota transplantation. Response to faecal microbiota transplantation was mainly influenced by the taxonomic composition of the donor's microbiota. Stool of donors with a high bacterial richness (observed species remission 946 ± 93 vs no response 797 ± 181 at 15367 rps) and a high relative abundance of Akkermansia muciniphila (3.3 ± 3.1% vs 0.1 ± 0.2%), unclassified Ruminococcaceae (13.8 ± 5.0% vs 7.5 ± 3.7%), and Ruminococcus spp. (4.9 ± 3.5% vs 1.0 ± 0.7%) were more likely to induce remission. In contrast antibiotic treatment alone (AB‐group) was poorly tolerated, probably because of a sustained decrease of intestinal microbial richness.
Conclusions
The taxonomic composition of the donor's intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in ulcerative colitis patients. The design of specific microbial preparation might lead to new treatments for ulcerative colitis.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29052237</pmid><doi>10.1111/apt.14387</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-4566-0806</orcidid><orcidid>https://orcid.org/0000-0003-1149-4782</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2018-01, Vol.47 (1), p.67-77 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5765501 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Anti-Bacterial Agents - administration & dosage Antibiotics Bacteria Colitis, Ulcerative - therapy Colon Donors Fecal Microbiota Transplantation - methods Feces - microbiology Gastrointestinal Microbiome Humans Inflammatory bowel disease Intestinal microflora Intestine Male Microbiota Middle Aged Original Prospective Studies Relative abundance Remission Remission Induction Ruminococcus Taxonomy Transplantation Treatment Outcome Ulcerative colitis Ulcerative Colitis and Faecal Transplant Donor Microbiota Young Adult |
| title | The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T06%3A00%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20taxonomic%20composition%20of%20the%20donor%20intestinal%20microbiota%20is%20a%20major%20factor%20influencing%20the%20efficacy%20of%20faecal%20microbiota%20transplantation%20in%20therapy%20refractory%20ulcerative%20colitis&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Kump,%20P.&rft.date=2018-01&rft.volume=47&rft.issue=1&rft.spage=67&rft.epage=77&rft.pages=67-77&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.14387&rft_dat=%3Cproquest_pubme%3E1974926095%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1974926095&rft_id=info:pmid/29052237&rfr_iscdi=true |